News from science and practice

News
News from science and practice

AGO-OVAR 27- WoO

AGO-OVAR 27 – WoO WoO: Window of Opportunity study on olaparib and durvalumab in histologically proven EOC Cohort A of the AGO-ovar 27 study has been fully recruited since January...

read more

NIS Niraparib – NOGGO-ov45 – CAROLIN

NIS Niraparib – NOGGO-ov45 – CAROLIN For patients with platinum-sensitive ovarian cancer who have no contraindications to niraparib This non-interventional observational study aims to investigate the long-term treatment with niraparib...

read more

Expression XVIII (18)

NOGGO S30/ Expression XVIII (18) INTERNATIONAL SURVEY ON THE IMPACT OF CRISES ON PATIENTS WITH GYNECOLOGICAL TUMORS Anxiety is a central issue in cancer patients with gynecologic diseases and can...

read more

EXPRESSION IX (9)

NOGGO S20 / ENGOTgyn4 – EXPRESSION IX (9) Long-term survival with gynecological cancer / Langzeitüberlebende mit gynäkologischen Krebserrankungen Based on the experience with Expression VI – Carolin meets HANNA, a...

read more

NOGGO S19 – EXPRESSION VIII (8)

NOGGO S19 – EXPRESSION VIII (8) For patients with a low-grade ovarian carcinoma (group A) or a borderline tumor of the ovary (group B – closed). Serous ovarian carcinoma is...

read more

EXPRESSION VI (6)

NOGGO S13 / ENGOT-ov40 – EXPRESSION VI (6)CAROLIN MEETS HANNA For patients with ovarian, fallopian tube and peritoneal cancer who were diagnosed at least 5 years ago NEW: Instead of...

read more

ENGOT-ov83 / CATALINA-2

ENGOT-ov83 / CATALINA-2 Therapeutic study to evaluate the efficacy and safety of the new compound TORL-1-23 in patients with advanced, platinum-resistant ovarian cancer CATALINA-2 is an international phase 2 trial...

read more

ENGOT-ov47-TR/ NOGGO-TR2 – HELP-ER

ENGOT-ov47-TR/ NOGGO-TR2 – HELP-ER OBSERVATIONAL STUDY ON HE4 SERUM LEVELS IN THE BLOOD OF PATIENTS WITH FIRST RECURRENCE OF OVARIAN CANCER The HELP-ER study was designed to improve the treatment...

read more

AGO-OVAR 2.46 / ENGOT-ov81 / RAMP 301

AGO-OVAR 2.46 / ENGOT-ov81 / RAMP 301 CLINICAL STUDY ON RECURRENT LOW-GRADE SEROUS OVARIAN CANCER The AGO-OVAR 2.46 / ENGOT-ov81 / RAMP 301 is a randomized, open-label phase III trial...

read more

NOGGO ov54 – SCOUT-1

NOGGO ov54 – Scout 1 Observational study to collect data from the everyday routine of patients with ovarian cancer undergoing initial therapy SCOUT-1 is a non-interventional study, a so-called observational...

read more

N-PLUS

NOGGO ov53/ ENGOT-ov62 – N-Plus The world’s first study with the aim of reducing the number of chemotherapy cycles and thus the duration of chemotherapy in patients who have undergone...

read more

NIS CAROLIN

NIS Niraparib – NOGGO-ov45 – CAROLIN For patients with platinum-sensitive ovarian cancer who have no contraindications to niraparib This non-interventional observational study aims to investigate the long-term treatment with niraparib...

read more

NOGGO S15 – FraStROC

NOGGO S15 – FraStROC Study for patients with recurrent or relapsed ovarian cancer. STUDY FOR PATIENTS WITH RECURRENT OR RELAPSED OVARIAN CANCER The FraStROC study is a non-interventional, prospective, multicenter...

read more

AGO-OVAR 28 / ENGOT-OV57

AGO-OVAR 28 / ENGOT-ov57 A randomized open-label phase III study evaluating niraparib alone versus the combination of niraparib and bevacizumab in patients receiving chemotherapy for newly diagnosed advanced ovarian cancer...

read more

EXPRESSION XX (20)

NOGGO S33/ Expression XX (20) SURVEY AMONG PATIENTS WITH GYNECOLOGICAL TUMORS ON HOW TO DELIVER BAD NEWS Breaking bad news is an essential part of everyday medical practice, especially in...

read more